On the 21st, the Seoul Hongneung Special Zone (Director Lim Hwan) and the Korea Drug Development Foundation (Director Park Young-min, KDDF) signed a business agreement at the KIST main building to foster an innovative ecosystem in new drug development and digital healthcare. This agreement aims to strengthen the global competitiveness of the domestic pharmaceutical and bio industries by linking the Hongneung Special Zone's business development achievements with the KDDF's full-cycle new drug development support system.
Under the agreement, the two organizations will pursue specific cooperative measures, including mutual support of research resources and infrastructure, technology matching, the establishment of a joint nurturing system tailored to each company's growth stage, and the establishment of a network of industry-academia-research-hospital R&D collaborations. Curebus, a Hongneung Innopolis resident, has successfully enhanced its technology through KDDF's non-clinical and lead substance support and has a track record of successfully transferring technology to global pharmaceutical companies. Zymedi, CellabMed, and Neuracle Genetics are also growing through phased support.
Lim Hwan, Director of the Hongneung Special Zone, said, "With this agreement, we will strive to establish Hongneung as a K-bio innovation hub in the fields of digital healthcare and new drug development." Park Young-min, Director of the KDDF, stated, "Through collaboration with the Hongneung Special Zone, we will identify companies with excellent technologies at an early stage and support their growth into global bio companies."
You must be logged in to post a comment.